Finally, we assessed Ceacam1 2/2 allo-BMT recipients on day 14 post-transplant. In correspondence with increased early GVHD mortality, Ceacam1 2/2 allo-BMT recipients showed increased large bowel damage and thymic GVHD ( Figure 2G -H).